je.st
news
Home
› New Cohorts From CheckMate -012 Assess Optimal Dosing Of Opdivo+Yervoy In The First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer
New Cohorts From CheckMate -012 Assess Optimal Dosing Of Opdivo+Yervoy In The First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer
2015-09-08 07:25:25| drugdiscoveryonline Home Page
Bristol-Myers Squibb Company recently announced updated results from the Opdivo (nivolumab)+Yervoy (ipilimumab) arms in CheckMate -012, a multi-arm Phase 1b trial evaluating Opdivo in patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC)
Tags: with
advanced
cell
treatment
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||